

6-12-2022

## **Process development for a flexible vaccine vector platform based on recombinant life virus**

Dieter Palmberger,

Shirin Preinsperger

Willibald Steinfellner

Matthias Müllner

Alois Jungbauer

*See next page for additional authors*

---

**Authors**

Dieter Palmberger,; Shirin Preinsperger; Willibald Steinfellner; Matthias Müllner; Alois Jungbauer; and Kerstin Rumpelmayr

---

## **PROCESS DEVELOPMENT FOR A FLEXIBLE VACCINE VECTOR PLATFORM BASED ON RECOMBINANT LIFE VIRUS**

Dieter Palmberger, Themis Bioscience GmbH, a subsidiary of Merck & Co., Inc.  
dieter.palmberger@merck.com

Shirin Preinsperger, acib – austrian centre of industrial biotechnology

Willibald Steinfeldner, acib – austrian centre of industrial biotechnology

Matthias Müllner, Themis Bioscience GmbH, a subsidiary of Merck & Co., Inc.

Alois Jungbauer, University of Natural Resources and Life Sciences, Vienna

Kerstin Rumpelmayr, Themis Bioscience GmbH, a subsidiary of Merck & Co., Inc.

**Key Words:** Life virus, Vaccines, Platform technology.

Vaccines are one of the most important, safe and efficient interventions to protect people from illness, disability and death. In recent years several new viral outbreaks where no vaccines are currently available were reported worldwide. Therefore, the development of flexible processes for the production of vaccines is urgently needed. This project aims at developing a platform process for the production of different viral vaccines. The core technology is based on the fact that large recombinant genes coding for selected, foreign antigens can be inserted into the genome of a well-established virus vaccination vector. The vaccine delivers the selected antigens directly to macrophages and dendritic cells, the most potent and effective antigen-presenting cells, thereby triggering a specific immune response to the selected antigens. As a replicating vector, the vaccine continuously expresses antigens even after immunization. This setup results in a powerful, antigen-focused immune response, which is expected to confer long-term immunity.

The challenges in production process design for such a vaccine are the establishment of a robust cell expansion and infection strategy as well the development of efficient downstream processing methods including several chromatography principals, ultra-diafiltration and employment of bio recognition principles. The implementation of a meaningful monitoring/characterization concept furthermore serves as a basis for reliable in-process control strategies.